FDA Legal, Regulatory & Compliance Issues, Part 1: FDA & DOJ Enforcement

In this first part of our series in collaboration with Arnall Golden Gregory LLP, Wayne chats with Gabriel Scannapieco, Partner at AGG and Co-chair of the firm's Life Sciences industry team. Together, they discuss trends in FDA and DOJ enforcement in 2026; how FDA and DOJ have approached the oversight of GLP-1 drugs; DOJ's non-prosecution agreement resolutions with Alibaba and AUS Merchant Services and what they mean for FDA enforcement; other products drawing attention from FDA and DOJ; recent FDA enforcement actions; what companies should do now and what should they watch for in the second half of the year related to enforcement; and much more. This episode and the rest of our series do not include the usual Headlines and Resources Links segments. To subscribe or find out more information about our podcast, visit FDAWatch.net (http://www.fdawatch.net/) . Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at [email protected] (mailto:[email protected]) . Music by Dvir Silver (https://pixabay.com/users/sonican-389...) from Pixabay (https://pixabay.com/music/?utm_source...) .